Roche launches blood test for genomic profiling

January 14, 2019 0 By FM

Roche announced the global availability of FoundationOne Liquid, a liquid biopsy test. FoundationOne Liquid can identify circulating tumour DNA in the blood of people living with cancer and can identify 70 of the most commonly mutated genes in solid tumours, including microsatellite instability, a genomic signature which may help inform cancer immunotherapy based treatment decisions.

FoundationOne Liquid helps comprehensive genomic profiling for people who have an insufficient or inadequate tissue, including those with advanced non-small cell lung cancer, where an estimated 15 percent of patients are not eligible for tissue biopsy and approximately 10 percent have a biopsy size that is insufficient to evaluate.

The liquid biopsy utilises circulating tumour DNA (ctDNA) test that complements FoundationOne CDx, a tissue-based test. The blood sample is sent to a Foundation Medicine lab where the test is performed using next-generation sequencing to analyse the four main classes of genomic alterations as well as microsatellite instability, an indicator that may help inform immunotherapy treatment decisions using ctDNA isolated from plasma derived from peripheral whole blood.